- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China6/27/16 11:30 pm EDT
Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reformsNEW YORK & HANGZHOU, China--(BUSINESS WIRE)--Pfizer Inc. today announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in China. This innovative facility will be Pfizer’s third biotechnology center globally and the first in Asia. It will ensure the local production of high-quality, affordable biosimilar medicines that willmore...
6/24/16 9:00 am EDT
Tender offer for all of the outstanding shares of Anacor common stock expired as scheduled immediately after 11:59 p.m., New York City time, on June 23, 2016
Pfizer and Anacor begin joint operations on June 24, 2016NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without interest but subject to required withholding of taxes). “Now that Anacor is part of Pfizer, we can accelerate our shared commitment to help patients with inflammatory disease,more...
6/23/16 4:00 pm EDTNEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 30-cent third-quarter 2016 dividend on the company’s common stock, payable September 1, 2016, to shareholders of record at the close of business on August 5, 2016. The third-quarter 2016 cash dividend will be the 311th consecutive quarterly dividend paid by Pfizer. Pfizer Inc. At Pfizer, we apply science and our global resources to bring therapies to people thatmore...
6/21/16 10:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 2, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2016 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.more...
Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination6/9/16 7:30 am EDT
Furyk Takes Time to Coach His Coach, His Father, and Other Adults 65 and Older About the Risk for Potentially Serious Infectious Diseases, Like Pneumococcal PneumoniaNEW YORK--(BUSINESS WIRE)--This Father’s Day, Jim Furyk will be thinking about more than just strategizing for the next Major as he joins Pfizer to encourage adults 65 and older to take responsibility for their health. On Father’s Day 2003, Furyk won a Major with his coach and father, Mike, by his side.1 This year, Jim will be one of 156 golfers to gather in Oakmont, PA, to play in one of professional golf’s major championship tournaments. For adults 65 and oldermore...
Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval6/8/16 7:15 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor of approval of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for its proposed indication, “management of pain severe enough to require daily, around-the-clock, long-term opioidmore...
Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ®) Providing Clinicians With Additional Information For The Treatment Of Moderate to Severe RA6/8/16 7:01 am EDT
More Than 20 Abstracts will be Featured at the European League Against Rheumatism Annual Congress (EULAR 2016)NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that 23 abstracts1, including research and analyses for tofacitinib citrate (XELJANZ®), will be featured at the upcoming European League Against Rheumatism (EULAR) Congress (June 8-11, London). The research being shared at the meeting provides new and additional information on the efficacy and safety profile of tofacitinib citrate, including its use as a single agent without methotrexate. “more...
Pfizer Announces Positive Top-Line Results from Second Phase 3 Trial of Oral XELJANZ® (Tofacitinib Citrate) in Adults with Psoriatic Arthritis6/7/16 7:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from Oral Psoriatic Arthritis triaL (OPAL) Beyond, the second Phase 3 study of XELJANZ® (tofacitinib citrate) being investigated in patients with active psoriatic arthritis (PsA). This study evaluated the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adult patients with active PsA who had an inadequate response to at least one tumor necrosis factor inhibitor (TNFimore...
6/6/16 9:00 am EDT
CHICAGO--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced results from the first pivotal, international, multicenter, open-label, Phase II study of avelumab*, which showed a 31.8% objective response rate (ORR) (28 of 88 patients; 95.9% CI: 21.9–43.1%†), in the pre-planned primary analysis of the study, and a manageable safety profile in patients with metastatic Merkel cell carcinoma (MCC) who were treated with avelumab in second ormore...
- First pivotal study for Merck KGaA, Darmstadt, Germany, and Pfizer’s investigational anti-PD-L1 antibody avelumab shows clinically meaningful tumor responses in pre-treated metastatic Merkel cell carcinoma (MCC)
- International, multicenter Phase II study results in metastatic MCC with 88 patients represents largest data set of any anti-PD-L1/PD-1 reported in this patient population
- Plan to submit to regulatory authorities based on these results
Pfizer Presents Promising Data from Next Generation ALK/ROS1 Inhibitor in Advanced Non-Small Cell Lung Cancer6/6/16 8:00 am EDT
Study Results Presented as Oral Abstract at ASCO 2016CHICAGO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer’s investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC), including patients with brain metastases. These data were presented today in an oral presentation atmore...